| First Author | Homma H | Year | 2021 |
| Journal | Life Sci Alliance | Volume | 4 |
| Issue | 7 | PubMed ID | 34130995 |
| Mgi Jnum | J:308471 | Mgi Id | MGI:6729555 |
| Doi | 10.26508/lsa.202101022 | Citation | Homma H, et al. (2021) DNA damage in embryonic neural stem cell determines FTLDs' fate via early-stage neuronal necrosis. Life Sci Alliance 4(7) |
| abstractText | The early-stage pathologies of frontotemporal lobal degeneration (FTLD) remain largely unknown. In VCP(T262A)-KI mice carrying VCP gene mutation linked to FTLD, insufficient DNA damage repair in neural stem/progenitor cells (NSCs) activated DNA-PK and CDK1 that disabled MCM3 essential for the G1/S cell cycle transition. Abnormal neural exit produced neurons carrying over unrepaired DNA damage and induced early-stage transcriptional repression-induced atypical cell death (TRIAD) necrosis accompanied by the specific markers pSer46-MARCKS and YAP. In utero gene therapy expressing normal VCP or non-phosphorylated mutant MCM3 rescued DNA damage, neuronal necrosis, cognitive function, and TDP43 aggregation in adult neurons of VCP(T262A)-KI mice, whereas similar therapy in adulthood was less effective. The similar early-stage neuronal necrosis was detected in PGRN(R504X)-KI, CHMP2B(Q165X)-KI, and TDP(N267S)-KI mice, and blocked by embryonic treatment with AAV-non-phospho-MCM3. Moreover, YAP-dependent necrosis occurred in neurons of human FTLD patients, and consistently pSer46-MARCKS was increased in cerebrospinal fluid (CSF) and serum of these patients. Collectively, developmental stress followed by early-stage neuronal necrosis is a potential target for therapeutics and one of the earliest general biomarkers for FTLD. |
